NanoPundit -Where Society, Science and the Law get really, really small.

Wednesday, January 26, 2005

Dendritic Nanotechnologies Picks Up Dendrimer Portfolio From Dow

Dendritic Nanotechnologies (DNT) reports that Dow has licensed its entire dendrimer portfolio to in exchange for a ‘significant’ equity stake (reportedly 31%). Dendrimers are interesting to pharmaceutical companies because of their drug delivery capabilityies. Starpharma, which held a 42% interest in DNT, will make an additional cash equity investment in DNT in exchange for exclusive rights to DNT and former Dow intellectual property for polyvalent, dendrimer-based pharmaceutical applications.

DNT’s portfolio includes more than 30 dendrimer patents and Dow has added 196 patents (41 patent families). Mike Pirc, Dow’s manager of intellectual stated “This move consolidates a great amount of the important intellectual property in the dendrimer field into one company.”

This strikes me as a perfect storm of technology companies coming to gether to advance the technology. Dow develops a pioneering new technology, DNT is an entrepreneurial company with some technology and a link to an end user and Starpharma can bring the technology to market to the benefit of everyone in the chain.


Post a Comment

<< Home